ALK-Abello A-S

Headquarters: Horsholm, Denmark

Employees: 2,537

CEO: Mr. Carsten Hellmann

show_chart OMXC: ALK.B -0.18%

Market Cap

kr.20.14 Billion

DKK as of Jan. 1, 2023

US$2.89 Billion

history Market Cap History

ALK-Abello A-S market capitalization over time

Evolution of ALK-Abello A-S market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of ALK-Abello A-S

Detailed Description

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.

Stocks & Indices

ALK-Abello A-S has the following listings and related stock indices.

Stock: OMXC: ALK.B

Stock: FSX: 4AJ



Boge Alle 6-8

Horsholm, 2970


Phone: 45 45 74 75 76

Fax: 45 45 74 86 90